Literature DB >> 7942609

Expression of the erbB-2 family of growth factor receptors and their ligands in breast cancers. Implication for tumor biology and clinical behavior.

S S Bacus1, C R Zelnick, G Plowman, Y Yarden.   

Abstract

Transmembrane receptor tyrosine kinases that bind to growth factors transmit signals that are essential to growth and differentiation. These receptors can be classified into groups based on their structure. One group implicated in the pathogenesis of breast cancer contains receptors belonging to the erbB family. This group includes the epidermal growth factor receptors, the HER-2/neu (erbB-2), HER-3, and HER-4. Despite the structural similarity of these receptors, HER-2/neu, HER-4, and HER-3 do not bind to any ligand of the epidermal growth factor receptor. However, a 44-kD glycoprotein called neu differentiation factor (neu differentiation factor/heregulin) has been isolated. This ligand phosphorylates the HER-2/neu receptor and binds directly to HER-4 and HER-3. The abundance of erbB receptors and their ligands in breast cancers points to their functional importance in the pathogenesis and biological behavior of breast cancers. Furthermore, these receptors and ligands may hold a promise for targeted therapy for breast cancer in the future.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7942609

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  19 in total

Review 1.  Roles of ErbB-3 and ErbB-4 in the physiology and pathology of the mammary gland.

Authors:  K L Carraway; C A Carraway; K L Carraway
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-04       Impact factor: 2.673

Review 2.  The ErbB receptors as targets for breast cancer therapy.

Authors:  J Albanell; J Baselga
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-10       Impact factor: 2.673

3.  A mechanistic study of tumor-targeted corrole toxicity.

Authors:  Jae Youn Hwang; Jay Lubow; David Chu; Jun Ma; Hasmik Agadjanian; Jessica Sims; Harry B Gray; Zeev Gross; Daniel L Farkas; Lali K Medina-Kauwe
Journal:  Mol Pharm       Date:  2011-10-25       Impact factor: 4.939

4.  Characterization of a neuregulin-related gene, Don-1, that is highly expressed in restricted regions of the cerebellum and hippocampus.

Authors:  S J Busfield; D A Michnick; T W Chickering; T L Revett; J Ma; E A Woolf; C A Comrack; B J Dussault; J Woolf; A D Goodearl; D P Gearing
Journal:  Mol Cell Biol       Date:  1997-07       Impact factor: 4.272

5.  Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer.

Authors:  P M Siegel; E D Ryan; R D Cardiff; W J Muller
Journal:  EMBO J       Date:  1999-04-15       Impact factor: 11.598

6.  Expression of growth hormone in canine mammary tissue and mammary tumors. Evidence for a potential autocrine/paracrine stimulatory loop.

Authors:  E van Garderen; M de Wit; W F Voorhout; G R Rutteman; J A Mol; H Nederbragt; W Misdorp
Journal:  Am J Pathol       Date:  1997-03       Impact factor: 4.307

7.  pcDNA3.1(-)-mediated ribozyme targeting of HER-2 suppresses breast cancer tumor growth.

Authors:  Pei He; Dan Zhu; Jun-Jian Hu; Ju Peng; Lian-Sheng Chen; Guang-Xiu Lu
Journal:  Mol Biol Rep       Date:  2009-05-15       Impact factor: 2.316

8.  Achyranthoside H methyl ester, a novel oleanolic acid saponin derivative from Achyranthes fauriei roots, induces apoptosis in human breast cancer MCF-7 and MDA-MB-453 cells via a caspase activation pathway.

Authors:  Motonori Fukumura; Hidehiro Ando; Yasuaki Hirai; Kazuo Toriizuka; Yoshiteru Ida; Yoshiyuki Kuchino
Journal:  J Nat Med       Date:  2009-01-09       Impact factor: 2.343

Review 9.  ErbB4/HER4: role in mammary gland development, differentiation and growth inhibition.

Authors:  Rebecca S Muraoka-Cook; Shu-Mang Feng; Karen E Strunk; H Shelton Earp
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-04-25       Impact factor: 2.673

Review 10.  Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer.

Authors:  Quanri Jin; Francisco J Esteva
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-11-25       Impact factor: 2.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.